US5187093A - Microorganisms useful in the process for the production of l-carnitine - Google Patents

Microorganisms useful in the process for the production of l-carnitine Download PDF

Info

Publication number
US5187093A
US5187093A US07/496,093 US49609390A US5187093A US 5187093 A US5187093 A US 5187093A US 49609390 A US49609390 A US 49609390A US 5187093 A US5187093 A US 5187093A
Authority
US
United States
Prior art keywords
carnitine
butyrobetaine
crotonobetaine
microorganisms
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/496,093
Other languages
English (en)
Inventor
Hans Kulla
Pavel Lehky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lonza AG
Original Assignee
Lonza AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lonza AG filed Critical Lonza AG
Priority to US07/496,093 priority Critical patent/US5187093A/en
Application granted granted Critical
Publication of US5187093A publication Critical patent/US5187093A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/007—Carnitine; Butyrobetaine; Crotonobetaine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/824—Achromobacter

Definitions

  • the invention relates to a process for the production of L-carnitine acid by biotechnical methods.
  • L-carnitine from ⁇ -butyrobetaine is known.
  • the ⁇ -butyrobetaine is brought into contact with a hydroxylase-enzyme, liberated from spores of Neurospora crassa (U.S. Pat. No. 4,371,618), in the presence of sodium-2-oxoglutarate, a reducing agent, an iron ion source and a hydroxyl group donor solvent.
  • Such process has the disadvantages of needing a multiplicity of co-factors.
  • stoichiometric quantities of 2-oxoglutarate are decarboxylized oxidatively to succinate.
  • Fe 2+ is needed as the O 2 -activator, ascorbate is used in order to keep the iron in the reduced form, and catalase is needed to destroy the harmful H 2 O 2 .
  • An object of the invention is to provide a process which overcomes the above-stated disadvantages of the prior art and mentioned related art.
  • Another object of the invention is to provide new microorganisms which do not have the disadvantages of the known microorganisms of the known processes and which would make it possible in a simple manner of not producing the racemate carnitine, but of producing enantio-selectively L-carnitine from crotonobetaine, butyrobetaine or mixtures thereof.
  • a further object of the invention is to provide a process for obtaining the new microorganisms.
  • the invention includes microorganisms which are capable of producing L-carnitine from crotonobetaine and/or ⁇ -butyrobetaine and do not catabolize the L-carnitine. Differing from the systems known the above-described prior art, the invention microorganisms use H 2 O and not the O 2 , as hydroxyl group donor, as was determined by examinations using H 2 18 O and 18 O 2 .
  • Such microorganisms are live.
  • Microorganisms which grow with betaine, ⁇ -butyrobetaine, crotonobetaine and L-carnitine as the C- and N-source, are mutated in the conventional or customary manner.
  • the mutated microorganisms are selected which are stable, do not catabolize L-carnitine and do not grow on L-carnitine, crotonobetaine or ⁇ -butyrobetaine, but do grow with betaine.
  • the microorganisms are selected which excrete L-carnitine and do not grow on L-carnitine, crotonobetaine or ⁇ -butyrobetaine, but do grow with betaine.
  • the mutated microorganisms are cultivated further in a betaine medium and these microorganisms which have been cultivated further are cultivated further preferably in an L-carnitine medium in order to carry out selection step (b).
  • the cultivation of strains growing with betaine, ⁇ -butyrobetaine, crotonobetaine and L-carnitine as a C- and N-source is carried out effectively in such a manner that one produces mixed cultures from mixtures of bacteria by inoculation of crotonobetaine nutritional solvents and that one starts from these, with the help of traditional microbiological techniques, pure cultures of microorganisms degrading crotonobetaine.
  • Methods usable effectively for the production of stable mutants are the frame-shift method, the deletion method and the transposon-insertion method.
  • the microorganisms mutated in this way are then subjected to selection step (b), after further cultivation in a betaine medium and transfer in an L-carnitine medium whereby means of known "counter-selecting agents" [P. Gerhardt et al., (eds.), Manual of Methods for General Bacteriology, Am. Soc. for Microbiology, (1981), pp. 222 to 242] those microorganisms are selected which are stable, do not catabolize L-carnitine and do not grow on L-carnitine, crotonobetaine or ⁇ -butyrobetaine, but do grow with betaine.
  • L-carnitine To produce L-carnitine according to the invention, live microorganisms themselves (not the enzymes released from treated spores or microorganisms) are used.
  • a preferred microorganism which grows with betaine, ⁇ -butyrobetaine, crotonobetaine and/or L-carnitine as C- and N-source is the strain HK 4 (DSM No. 2938) and its descendants and mutants.
  • the new strain DSM 2938 was deposited on Mar. 3, 1984 in the German collection of microorganisms (DSM), Deutschen fuer Biotechntreu Anlagen mbH., Griesebachstrasse 8, 4300 Goettingen, Federal Republic of Germany, under the designation or number DSM 2938.
  • Such deposit of a culture of such new strain of microorganism in such depository affords permanence of the deposit and ready accessibility thereto by the public if a patent is granted, under conditions which assure (a) that access to the culture will be available during the pendency of the patent application to one determined by the Commissioner to be entitled thereto under 37 C.R.R. 1.14 and 35 U.S.C. 122, and (b) that all restrictions on the availability to the public of the culture so deposited will be irrevocably removed upon the granting of the patent.
  • the applicants or their assigns have provided assurance of permanent availability of the culture to the public through such depository.
  • a preferred microorganism is a mutant of the previously described microorganism, which is stable, does not catabolize L-carnitine, but excretes, and does not grow on L-carnitine, crotonobetaine and ⁇ -butyrobetaine, but does indeed grow on betaine, is the strain HK 13 (DSM No. 2903).
  • the new strain DSM 2903 was deposited on Jan. 23, 1984, in the German collection of microorganisms (DSM), Deutschen fuer BiotechntreuschmbH., Griesebachstrasse 8, 4300 Goettingen, Federal Republic of Germany, under the designation or number DSM 2903.
  • Such deposit of a culture of such new strain of microorganism in such depository affords permanence of the deposit and ready accessibility thereto by the public if a patent is granted, under conditions which assure (a) that access to the culture will be available during the pendency of the patent application to one determined by the Commissioner to be entitled thereto, under 37 C.F.R. 1.14 and 35 U.S.C. 122, and (b) that all restrictions on the availability to the public of the culture so deposited will be irrevocably removed upon the granting of the patent.
  • the applicants or their assigns have provided assurance of permanent availability of the culture to the public through such depository.
  • the new strain DSM 3225 was deposited on Feb. 8, 1985, in the German collection of microorganisms (DSM), Deutschen fuer Biotechntreu Anlagen mbH., Griesebachstrasse 8, 4300 Goettingen, Federal Republic of Germany, under the designation or number DSM 3225.
  • Such deposit of a culture of such new strain of microorganisms in such depository affords permanence of the deposit and ready accessibility thereto by the public if a patent is granted, under conditions which assure (a) that access to the culture will be available during the pendency of the patent application to one determined by the Commissioner to be entitled thereto under 37 C.F.R. 1.14 and 35 U.S.C. 122, and (b) that all restrictions on the availability to the public of the culture so deposited will be irrevocably removed upon the granting of the patent.
  • the applicants or their assigns have provided assurance of permanent availability of the culture to the public through such depository.
  • the process for the production of L-carnitine can be carried out effectively in such a way that a preculture of a microorganism, preferably of a microorganism with the designation HK 13 (DSM 2903) is cultivated in a sterilized, preferably vitamin containing mineral medium [Kulla et al., Arch. Microbiol. 135, 1 to 7 (1983)] at 20° C. to 40° C., preferably at 30° C., at an effective pH value of 6 to 8,preferably 7, for 20 to 50 hours, preferably for 30 to 40 hours.
  • This preculture contains effectively 0.1 to 10 percent by weight, preferably 0.5 to 5 percent by weight, of choline, glutamate, acetate, dimethylglycine or betaine as a growth substrate. Particularly preferred is betaine in quantity of 0.5 to 5 percent by weight.
  • ⁇ -butyrobetaine crotonobetaine or mixture thereof in a quantity of 0.1 to 10 percent by weight, preferably 0.5 to 5 percent by weight, related to the reaction medium.
  • the ⁇ -butyrobetaine or crotonobetaine can be present as a hydrochloride salt or as a free inner salt as well as in the form of one of its derivatives.
  • the crotonobetaine, ⁇ -butyrobetaine or mixtures thereof that are to be converted are present in a concentration of 0.1 to 10 percent by weight, preferably 0.5 to 5 percent by weight.
  • the growth substrate, choline glutamate, acetate, dimethylglycine and/or betaine are used effectively in the concentrations used in the case of the preculture.
  • the cultivation conditions of the further cultivation are adapted corresponding to the cultivation conditions of the precultivation. Therefore, the temperatures effectively vary between 20° and 40° C., effectively vary between 20° and 40° C., most effectively at 30° C., and the pH value is kept as a rule between 6 to 8, advantageously at 7.
  • L-carnitine carried out in this manner comes to a standstill after 20 to 30 hours.
  • concentration of L-carnitine is then equivalent to the quantity of ⁇ -butyrobetaine or crotonobetaine as a rule.
  • the cells can be centrifuged or filtered off and can be used as inoculation material for a new culture.
  • the L-carnitine can be brought out from the supernatant by means of cation exchanger chromatography and can be purified by recrystallization.
  • the invention process for the production of L-carnitine can also be carried out in a continuous manner by allowing the cells to grow in a chemostate at an effective dilution rate of 0.04 to 0.2 h -1 , preferably at 0.06 to 0.08 h -1 , at conditions analagous to those in the case of the batch culture.
  • the invention involves the production of L-carnitine from crotonobetaine and/or ⁇ -butyrobetain by way of microbiology.
  • a biologically pure culture may include a slightly-contaminated culture, as such cultures are also productive (useful). To be biologically effective, slight contamination can be present in the culture of live microorganisms.
  • Microorganisms were extracted from soil using neutral phosphate buffer solution by stirring. Larger components were subsequently separated through filter paper. A crotonobetaine nutrient solution was inoculated with the bacteria mixture obtained in this way up to a slight cloudiness. After 9 days, the cloudiness had risen to ninety-fold as a measure of the cell concentration. Crotonobetaine has disappeared completely from the solution and ammonium was proven to exist as a degradation product. From the mixed culture and with the help of traditional microbiological techniques (solidified agar culture media), pure cultures of microorganisms decomposing crotonobetaine were started. A culture was selected for further work and was named HK 4 (DSM 2938). This strain also grew with ⁇ -butyrobetaine, L-carnitine and betaine.
  • a stable carnitine dehydrogenase negative mutant should not be able to further catabolize L-carnitine built up from ⁇ -butyrobetaine or crotonobetaine and, instead it should excrete in the ideal case.
  • a culture of strain HK 4 (DSM 2938) was stably mutagenized with "acridin mutagen ICR 191", 5 microgram per ml, in a succinate medium as prescribed [J. H. Miller, Experiments in Molecular Genetics, Cold Spring Harbor Laboratory, 1972, pp. 121 to 179]. After that the cells according to standard were allowed to grow in a "nutrient broth" for the expression of the mutation. Then the culture was transferred into a betaine medium. A L-carnitine medium was inoculated with the fully grown culture.
  • the cells isolated in such a way grew into colonies and were examined individually.
  • the mutant HK 13 (DSM 2903) was selected. Stably, it had no carnitine-dehydrogenase and correspondingly no longer grew with L-carnitine, ⁇ -butyrobetaine or crotonobetaine, but it indeed did with betaine.
  • this strain converted crotonobetaine or ⁇ -butyrobetaine into L-carnitine and excreted it.
  • the concentration of L-carnitive was measured in the supernatant (19.8 l) by way of enzymatic analysis.
  • the excess contained 4.26 mg of L-carnitine per ml. This corresponded to a yield of 95.0 percent, calculated on the quantity of crotonobetaine-chloride used. Educts or other impurities were not found to exist in the NMR spectrum.
  • the L-carnitine was brought out by means of cation exchanger chromatography from the supernatant and was purified by recrystallization.
  • a 5-l preculture of strain HK 13 was cultivated in a vitamin-containing medium (according to Example 1), which contained 1 percent of choline and 0.6 percent of ⁇ -butyrobetaine-chloride, at pH 7.0 and 30° C. for 32 hours.
  • a culture of 15 l of medium of the same composition was inoculated and was cultivated under the same conditions as in Example 1.
  • the cells were separated by microfiltration (Amicon Hollow-fiber cartridge). This cell mass was used for the further production of L-carnitine.
  • the concentration of L-carnitine was enzymatically determined in the filtrate (19.6 l).
  • the filtrate contained 5.3 mg of L-carnitine per ml. This corresponded to an analytical yield of 97.6 percent, calculated on the quantity of ⁇ -butyrobetaine-chloride used. According to the NMR analysis, no educts or other foreign organic by-products could be proven to exist in the filtrate. Therefore, the L-carnitine was isolated from the solution in a known manner, for example, by means of azeotropic distillation (German Patent No. 2,300,492).
  • a fermentor equipped for continuous culture which contained 1.5 l of a vitamin containing mineral medium (according to Example 1) with 1.5 percent of betaine and 1.0 percent of ⁇ -butyrobetaine-chloride was inoculated with 150 ml of strain 13 (DSM 2903) preculture of the same medium. After 20 hours of aerobic cultivation at 30° C. and pH 7.0, the culture had grown up and the continuous operation was started at a flow rate of 0.1 l/h. The culture solution flowing out of the fermentor was caught in a vessel cooled at 4° C. the cells were removed by centrifugation. According to enzymatic analysis, the supernatant contained 8.8 g of L-carnitine per 1 of culture.
  • Example 4 was repeated using strain HK 1331 b (DSM 3225), whereby choline was substituted for 0.3 percent betaine plus 0.3 percent L-glutamate.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Prostheses (AREA)
  • Eye Examination Apparatus (AREA)
  • Catalysts (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US07/496,093 1984-03-29 1990-03-15 Microorganisms useful in the process for the production of l-carnitine Expired - Lifetime US5187093A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US07/496,093 US5187093A (en) 1984-03-29 1990-03-15 Microorganisms useful in the process for the production of l-carnitine

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CH160084 1984-03-29
CH1600/84 1984-03-29
US71769885A 1985-03-29 1985-03-29
US11792187A 1987-11-06 1987-11-06
US07/496,093 US5187093A (en) 1984-03-29 1990-03-15 Microorganisms useful in the process for the production of l-carnitine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11792187A Continuation 1984-03-29 1987-11-06

Publications (1)

Publication Number Publication Date
US5187093A true US5187093A (en) 1993-02-16

Family

ID=4214209

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/496,093 Expired - Lifetime US5187093A (en) 1984-03-29 1990-03-15 Microorganisms useful in the process for the production of l-carnitine

Country Status (25)

Country Link
US (1) US5187093A (enrdf_load_stackoverflow)
EP (1) EP0158194B1 (enrdf_load_stackoverflow)
JP (1) JPS60224488A (enrdf_load_stackoverflow)
CN (1) CN1004146B (enrdf_load_stackoverflow)
AT (1) ATE64154T1 (enrdf_load_stackoverflow)
AU (1) AU585216B2 (enrdf_load_stackoverflow)
BG (1) BG50282A3 (enrdf_load_stackoverflow)
BR (1) BR8501374A (enrdf_load_stackoverflow)
CA (1) CA1265757A (enrdf_load_stackoverflow)
CS (1) CS273163B2 (enrdf_load_stackoverflow)
DD (1) DD232310A5 (enrdf_load_stackoverflow)
DE (1) DE3583058D1 (enrdf_load_stackoverflow)
DK (1) DK165191C (enrdf_load_stackoverflow)
ES (1) ES8602940A1 (enrdf_load_stackoverflow)
FI (1) FI86889C (enrdf_load_stackoverflow)
HU (1) HU193744B (enrdf_load_stackoverflow)
IE (1) IE58045B1 (enrdf_load_stackoverflow)
IL (1) IL74552A (enrdf_load_stackoverflow)
IN (1) IN164247B (enrdf_load_stackoverflow)
NO (1) NO164918C (enrdf_load_stackoverflow)
PL (1) PL145712B1 (enrdf_load_stackoverflow)
RO (1) RO92477B (enrdf_load_stackoverflow)
SU (1) SU1435159A3 (enrdf_load_stackoverflow)
YU (1) YU45708B (enrdf_load_stackoverflow)
ZA (1) ZA851959B (enrdf_load_stackoverflow)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304723A (en) * 1990-05-31 1994-04-19 Consortium Fur Elektrochemische Industrie Gmbh Biologically pure culture of maltopentaose forming amylase producing alkalophilic bacteria
US6342034B1 (en) 1997-07-28 2002-01-29 Samsung Fine Chemicals Co., Ltd. Process for the preparation of L-carnitine
US20040241090A1 (en) * 2003-05-29 2004-12-02 Pettegrew Jay W. Compounds, compositions and methods for medical imaging of neuropsychiatric disorders
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
US20060292547A1 (en) * 2002-02-07 2006-12-28 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US7407778B2 (en) 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59183694A (ja) * 1983-04-05 1984-10-18 Hamari Yakuhin Kogyo Kk 光学活性なカルニチンの生化学的製造法
JPS59192095A (ja) * 1983-04-13 1984-10-31 Ajinomoto Co Inc Ｌ−カルニチンの製造法
DD221905B1 (de) * 1983-11-03 1987-03-18 Univ Leipzig Verfahren zur herstellung von l(-)-carnitin und seinen derivaten
JPS62275689A (ja) * 1985-12-09 1987-11-30 Bio-Le Kk Ｌ−カルニチンの製造法
MX170707B (es) * 1989-07-28 1993-09-08 Lonza Ag Procedimiento para la produccion discontinua de l-carnitina por transformacion microbiologica de crotonobetaina y gama-butirobetaina
DE4106375A1 (de) * 1991-02-28 1992-09-03 Degussa Eine l-carnitin-amidase produzierender mikroorganismus, l-carnitin-amidase, verfahren zu deren gewinnung und deren verwendung
CN1058995C (zh) * 1996-11-08 2000-11-29 江苏省微生物研究所 L-肉碱或其盐的制备方法
DE19749480A1 (de) * 1997-11-08 1999-05-20 Univ Leipzig Verfahren zur Herstellung von L-Carnitin aus Crotonobetain
DE50209655D1 (de) * 2001-01-31 2007-04-19 Lonza Ag Mikrobiologisches verfahren zur herstellung von l-carnitin
BRPI0612611A2 (pt) * 2005-07-05 2010-12-07 Lonza Ag processo de secagem por pulverização para produzir um pó ou granulado seco de carnitina

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2313573A (en) * 1938-01-17 1943-03-09 Gen Aniline & Film Corp Capillary active compounds and process of preparing them
US2367878A (en) * 1939-05-04 1945-01-23 Hoffmann La Roche Betaine esters
DE1903076A1 (de) * 1968-01-30 1969-08-07 Ugine Kuhlmann Verfahren zur Herstellung von 4-Acyloxybuttersaeureestern
US3466364A (en) * 1964-11-30 1969-09-09 Daiichi Seiyaku Co Method of treating alopecia and novel compositions therefor
DE1939759A1 (de) * 1968-08-29 1970-03-05 Gulf Research Development Co Verfahren zur Herstellung von Cyclopropylamin
US3711549A (en) * 1970-05-19 1973-01-16 Gulf Research Development Co Process for manufacturing cyclopropylamine
US3796632A (en) * 1971-12-10 1974-03-12 Toray Industries Process for racemizing alpha-amino-epsilon-caprolactam
DE2751134A1 (de) * 1977-11-16 1979-05-17 Degussa Verfahren zur herstellung von gamma-chlorcarbonsaeureestern
US4371618A (en) * 1980-06-24 1983-02-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Process for enzymatically producing L-carnitine
EP0122794A2 (en) * 1983-04-13 1984-10-24 Ajinomoto Co., Inc. Method for producing L-carnitine
US4567140A (en) * 1982-04-22 1986-01-28 Hoechst Aktiengesellschaft Microbial polysaccharides, process for their preparation, microorganisms suitable for this and use of the polysaccharides
US4708936A (en) * 1985-02-27 1987-11-24 Lonza Ltd. Process for the continuous production of L-carnitine
US4806282A (en) * 1986-04-24 1989-02-21 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Process for preparing gamma-butyrobetaine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD221905B1 (de) * 1983-11-03 1987-03-18 Univ Leipzig Verfahren zur herstellung von l(-)-carnitin und seinen derivaten

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2313573A (en) * 1938-01-17 1943-03-09 Gen Aniline & Film Corp Capillary active compounds and process of preparing them
US2367878A (en) * 1939-05-04 1945-01-23 Hoffmann La Roche Betaine esters
US3466364A (en) * 1964-11-30 1969-09-09 Daiichi Seiyaku Co Method of treating alopecia and novel compositions therefor
DE1903076A1 (de) * 1968-01-30 1969-08-07 Ugine Kuhlmann Verfahren zur Herstellung von 4-Acyloxybuttersaeureestern
GB1198414A (en) * 1968-01-30 1970-07-15 Ugine Kuhlmann Process for the Preparation of 4-acyloxybutyric Acid Esters
DE1939759A1 (de) * 1968-08-29 1970-03-05 Gulf Research Development Co Verfahren zur Herstellung von Cyclopropylamin
US3711549A (en) * 1970-05-19 1973-01-16 Gulf Research Development Co Process for manufacturing cyclopropylamine
US3796632A (en) * 1971-12-10 1974-03-12 Toray Industries Process for racemizing alpha-amino-epsilon-caprolactam
DE2751134A1 (de) * 1977-11-16 1979-05-17 Degussa Verfahren zur herstellung von gamma-chlorcarbonsaeureestern
US4371618A (en) * 1980-06-24 1983-02-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Process for enzymatically producing L-carnitine
US4567140A (en) * 1982-04-22 1986-01-28 Hoechst Aktiengesellschaft Microbial polysaccharides, process for their preparation, microorganisms suitable for this and use of the polysaccharides
EP0122794A2 (en) * 1983-04-13 1984-10-24 Ajinomoto Co., Inc. Method for producing L-carnitine
US4650759A (en) * 1983-04-13 1987-03-17 Ajinomoto Company, Incorporated Method of producing L-carnitine
US4708936A (en) * 1985-02-27 1987-11-24 Lonza Ltd. Process for the continuous production of L-carnitine
US4806282A (en) * 1986-04-24 1989-02-21 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Process for preparing gamma-butyrobetaine

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
Askens et al., J. Chem. Soc., pp. 103ff (1959). *
G. Lindstedt et al., Biochemisrty, 6, 1967, pp. 1262 1270. *
G. Lindstedt et al., Biochemisrty, 6, 1967, pp. 1262-1270.
G. Lindstedt et al., Biochemistry 16, 1977, pp. 2181 2188. *
G. Lindstedt et al., Biochemistry 16, 1977, pp. 2181-2188.
Gerhardt, P. "Manual of Methods for General Bacteriology", Am. Soc. for Microbiology (1981), pp. 222 to 242.
Gerhardt, P. Manual of Methods for General Bacteriology , Am. Soc. for Microbiology (1981), pp. 222 to 242. *
Kulla H. G., et al., Arch. Microbiol. 135, (1983), pp. 1 to 7. *
Miller, Experiments in Molecular Genetics , (1972), pp. 121 180. *
Miller, Experiments in Molecular Genetics, (1972), pp. 121-180.
Miller, J. H., "Experiments in Molecular Genetics", Cold Spring Laboratory, (1972), pp. 121 to 179.
Miller, J. H., Experiments in Molecular Genetics , Cold Spring Laboratory, (1972), pp. 121 to 179. *
Oraston et al., Biochemical and Biophysical Research , vol. 36, No. 1, (1969), pp. 179 184. *
Oraston et al., Biochemical and Biophysical Research, vol. 36, No. 1, (1969), pp. 179-184.
Ornston, L. N., et al., Biochem. Biophys. Res. Commun. 35 (1969) pp. 179 to 184. *
Perry s Chemical Engineer s Handbook , 6th Edition, (1984), p. 27 7. *
Perry's Chemical Engineer's Handbook, 6th Edition, (1984), p. 27-7.
Seim et al., Eur. Cong. Biotechnol. , 3rd, vol. 1, 481 6 (1984). *
Seim et al., Eur. Cong. Biotechnol., 3rd, vol. 1, 481-6 (1984).
Vandecasteele, J. P., Applied Environ. Microbiol. 39, (1980), pp. 327 to 334. *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304723A (en) * 1990-05-31 1994-04-19 Consortium Fur Elektrochemische Industrie Gmbh Biologically pure culture of maltopentaose forming amylase producing alkalophilic bacteria
US6342034B1 (en) 1997-07-28 2002-01-29 Samsung Fine Chemicals Co., Ltd. Process for the preparation of L-carnitine
US20060292547A1 (en) * 2002-02-07 2006-12-28 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US7407778B2 (en) 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US20040241090A1 (en) * 2003-05-29 2004-12-02 Pettegrew Jay W. Compounds, compositions and methods for medical imaging of neuropsychiatric disorders
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
US7815894B2 (en) 2003-05-29 2010-10-19 Jay W. Pettegrew Compounds, compositions and methods for medical imaging of neuropsychiatric disorders

Also Published As

Publication number Publication date
NO164918B (no) 1990-08-20
DE3583058D1 (de) 1991-07-11
FI86889B (fi) 1992-07-15
ES541663A0 (es) 1985-12-01
BR8501374A (pt) 1985-11-26
AU4019285A (en) 1985-10-03
FI86889C (fi) 1992-10-26
ES8602940A1 (es) 1985-12-01
SU1435159A3 (ru) 1988-10-30
IN164247B (enrdf_load_stackoverflow) 1989-02-04
CN1004146B (zh) 1989-05-10
DK165191B (da) 1992-10-19
BG50282A3 (en) 1992-06-15
PL145712B1 (en) 1988-10-31
DD232310A5 (de) 1986-01-22
NO164918C (no) 1990-11-28
ATE64154T1 (de) 1991-06-15
AU585216B2 (en) 1989-06-15
IE850533L (en) 1985-09-29
CA1265757A (en) 1990-02-13
IL74552A (en) 1988-12-30
EP0158194A2 (de) 1985-10-16
FI850781A0 (fi) 1985-02-26
NO851261L (no) 1985-09-30
JPS60224488A (ja) 1985-11-08
EP0158194B1 (de) 1991-06-05
CS273163B2 (en) 1991-03-12
HUT37653A (en) 1986-01-23
YU50485A (en) 1987-12-31
IL74552A0 (en) 1985-06-30
YU45708B (sh) 1992-07-20
PL252628A1 (en) 1986-02-25
DK138085A (da) 1985-09-30
HU193744B (en) 1987-11-30
IE58045B1 (en) 1993-06-16
DK165191C (da) 1993-03-01
ZA851959B (en) 1985-11-27
DK138085D0 (da) 1985-03-27
RO92477A (ro) 1987-09-30
CS222085A2 (en) 1990-07-12
FI850781L (fi) 1985-09-30
RO92477B (ro) 1987-10-01
CN85101191A (zh) 1987-06-10
EP0158194A3 (en) 1987-07-22

Similar Documents

Publication Publication Date Title
US5187093A (en) Microorganisms useful in the process for the production of l-carnitine
US4708936A (en) Process for the continuous production of L-carnitine
EP0449648B1 (en) Process for producing R(-)-mandelic acid and derivatives thereof
US4529697A (en) Process for producing L-glutamic acid by fermentation
KR100198039B1 (ko) 발효에 의한 l-글루탐산의 제조방법
US5082777A (en) Process for the production of 6-hydroxynicotinic acid
US4758518A (en) D-2-haloalkanoic acid halidohydrolase
EP0120208B1 (de) Mikrobiologisch hergestellte L-Phenylalanin-Dehydrogenase, Verfahren zu ihrer Gewinnung und ihre Verwendung
EP0188712B1 (de) Verfahren zur Gewinnung von Phenylalanin-Dehydrogenase enthaltenden Mikroorganismen und deren Verwendung zur Herstellung von L-alpha-Aminosäuren
EP0229219B1 (en) Urease and process for preparation thereof
JPH04316490A (ja) ６−ヒドロキシピコリン酸の微生物学的製法
DE3247703C2 (de) Verfahren zur Gewinnung von L-Threonin
EP0434393B1 (en) Process for preparation of R-(-)-3-halogeno-1,2-propanediol by treatment with microorganism
EP0410430B1 (de) Verfahren zur diskontinuierlichen Herstellung von L-Carnitin auf mikrobiologischem Weg
EP0179864B1 (en) Process for preparing l-carnitine
EP1018546B1 (en) Microorganisms producing 5-aminolevulinic acid and processes for producing 5-aminolevulinic acid by using the same
EP0076516B1 (en) Method for fermentative production of l-proline
JP2586283B2 (ja) 微生物学的手段によってｌ−カルニチンを製造する方法
Shiio et al. Genetically altered repression pattern of purine nucleotide synthesizing enzymes and inosine production in 8-azaguanine resistant mutants of Bacillus subtilis
US5266482A (en) Agrobacterium useful for the microbiological process for the production of hydroxylated pyrazine derivatives
EP0643139A2 (en) Process for preparing indigo
CZ279298B6 (cs) Mikroorganismy Alcaligenes faecalis DSM 6335 a způsob mikrobiologické výroby kyseliny 6-hydroxypikolinové
JPH0647395A (ja) ２−ナフタレンスルホン酸の分解法
JPH06153915A (ja) ５−アミノレブリン酸生産微生物および５−アミノレブリン酸の製造方法
JPS5860995A (ja) 発酵法によるｌ−プロリンの製法

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12